Rentschler Biotechnologie GmbH & Co. Appoints New Chief Business Officer
Published: Mar 07, 2013
"Mr. Ternes is an excellent addition to Rentschler's management board," says Dr. Nikolaus F. Rentschler, CEO and owner of Rentschler. "With his broad experience in the contract manufacturing business, he has a keen understanding of technology, a strong customer focus, and a proven track record for achieving success.”
Frank Ternes brings more than 25 years of experience from Operations and Technology at Boehringer Ingelheim where he last served as Senior Vice President of Biopharmaceutical Contract Manufacturing.
Mr. Ternes holds a degree equivalent to a master’s degree in economics from the University of Bonn, Germany.
Rentschler Biotechnologie GmbH is a global full-service contract manufacturer with more than 35 years of experience in the development, production and approval of biopharmaceuticals in compliance with international GMP standards (EMA/FDA). Rentschler has nine GMP suites with volumes of 30, 50, 250, 500, 1,000 and 2,500 liters, allowing the production of material for clinical trials (phases I to III) and for market supply and also provides regulatory advice, protein analytics, quality control, and the sterile filling of syringes and injection vials. The company is family-owned and independent and has currently about 650 employees.
Rentschler Biotechnologie GmbH
Phone: +49 7392 701-478